[EXEL] Exelixis, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.41 Change: 0.47 (3.15%)
Ext. hours: 15.31 Change: -0.1 (-0.65%)

chart EXEL

Refresh chart

Strongest Trends Summary For EXEL

EXEL is in the medium-term down -15% below S&P in 1 month and up 40% above S&P in 6 months. In the long-term up 400% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Phar

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 43.07% Sales Growth - Q/Q27.68% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-80.97% ROE156.1% ROI-102.16%
Current Ratio2.13 Quick Ratio2.09 Long Term Debt/Equity5.49 Debt Ratio-0.4
Gross Margin91.55% Operating Margin-615.77% Net Profit Margin-774.12% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-220 K Cash From Investing Activities49.9 M Cash From Operating Activities-45.09 M Gross Profit8.62 M
Net Profit-35.17 M Operating Profit-22.76 M Total Assets282.93 M Total Current Assets125.04 M
Total Current Liabilities58.68 M Total Debt368.43 M Total Liabilities429.69 M Total Revenue9.39 M
Technical Data
High 52 week31.36 Low 52 week13.65 Last close22.78 Last change-1.85%
RSI36.29 Average true range0.77 Beta1.53 Volume4.05 M
Simple moving average 20 days-1.57% Simple moving average 50 days7.48% Simple moving average 200 days16.09%
Performance Data
Performance Week-1.51% Performance Month9.89% Performance Quart52.37% Performance Half10.48%
Performance Year-24.62% Performance Year-to-date15.81% Volatility daily2.78% Volatility weekly6.22%
Volatility monthly12.74% Volatility yearly44.13% Relative Volume263.48% Average Volume4.4 M
New High New Low

News

2019-03-18 14:26:28 | Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'

2019-03-18 13:06:50 | Signal Says Buy Options Insurance on This Biotech

2019-03-14 17:50:09 | Exelixis EXEL Gains As Market Dips: What You Should Know

2019-03-14 17:00:25 | How a biotech company navigated bay bureaucracy to set up a commuter ferry service

2019-03-14 09:30:01 | Why Is Exelixis EXEL Up 12.1% Since Last Earnings Report?

2019-03-13 17:31:31 | 5 Biotech Stocks to Keep an Eye on in 2019

2019-03-13 13:21:01 | Why Exelixis, Inc. NASDAQ:EXEL Is An Attractive Investment To Consider

2019-03-12 10:01:02 | Pfizer's PFE Kidney Cancer Drug Combo Gets EMA's Validation

2019-03-08 17:50:10 | Exelixis EXEL Dips More Than Broader Markets: What You Should Know

2019-03-05 16:05:00 | Exelixis Announces Webcasts of Investor Conference Presentations in March

2019-03-05 07:15:00 | 3 Best Biotech Bargain Stocks on the Market Right Now

2019-02-22 16:48:42 | Exelixis Inc EXEL Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-19 07:17:00 | Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster

2019-02-15 06:52:11 | New Strong Sell Stocks for February 15th

2019-02-14 08:40:01 | Implied Volatility Surging for Exelixis EXEL Stock Options

2019-02-13 18:51:33 | Cramer's lightning round: These are the two pot stocks I'm recommending

2019-02-13 15:47:00 | Exelixis Grabs 90% of First Place

2019-02-13 13:25:06 | Exelixis EXEL Earnings, Revenues Beat Estimates in Q4

2019-02-13 09:35:00 | Exelixis Rises as Fourth-Quarter Earnings Beat Estimates

2019-02-13 09:08:00 | These 'Small Ball' Names Will Outperform the Market in 2019

2019-02-13 07:49:26 | The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

2019-02-13 03:29:53 | Edited Transcript of EXEL earnings conference call or presentation 12-Feb-19 10:00pm GMT

2019-02-12 23:08:54 | Exelixis, Inc EXEL Q4 2018 Earnings Conference Call Transcript

2019-02-12 17:47:22 | Exelixis: 4Q Earnings Snapshot

2019-02-12 17:20:10 | Exelixis EXEL Tops Q4 Earnings and Revenue Estimates

2019-02-12 16:06:00 | Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

2019-02-12 16:05:00 | Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts

2019-02-12 15:00:00 | Exelixis, Inc. to Host Earnings Call

2019-02-12 08:16:04 | Q4 Earnings Preview For Exelixis

2019-02-12 08:04:55 | The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

2019-02-10 17:37:42 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

2019-02-08 08:06:45 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-02-07 16:31:09 | Exelixis EXEL to Report Q4 Earnings: What's in Store?

2019-02-07 16:05:00 | Exelixis to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 on February 14, 2019

2019-02-06 10:29:54 | Here’s What Exelixis, Inc.’s NASDAQ:EXEL P/E Ratio Is Telling Us

2019-02-05 10:30:03 | Exelixis EXEL Earnings Expected to Grow: Should You Buy?

2019-02-01 08:25:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Exelixis, Varian Medical, DXC Technology, Bridgepoint Education, Armstrong World Industries, and Immunomedics — New Research Emphasizes Economic Growth

2019-01-29 16:05:00 | Exelixis to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 12, 2019

2019-01-22 08:07:03 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-01-18 17:45:10 | Exelixis EXEL Stock Sinks As Market Gains: What You Should Know

2019-01-17 10:18:03 | Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

2019-01-15 16:48:00 | Here’s your guide to the upcoming biotechnology takeover wave

2019-01-15 09:32:33 | How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approval

2019-01-15 08:49:01 | Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer

2019-01-15 08:06:37 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-01-15 07:50:00 | Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine

2019-01-14 18:05:11 | 5 Reasons Why Investors Should Buy Exelixis EXEL in 2019

2019-01-14 17:48:00 | Exelixis stock up more than 4% after FDA drug approval

2019-01-14 17:38:00 | Exelixis Announces U.S. FDA Approval of CABOMETYX® cabozantinib Tablets for Previously Treated Hepatocellular Carcinoma

2019-01-13 15:50:01 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials